Keywords: Abbott Labs, Meridia, Obesity, USA, FDA, Canada, Australia

Abbott Labs agrees to pull its obesity drug Meridia off US and other markets

Article | 11 October 2010

Print This

US health care major Abbott Laboratories (NYSE: ABT) has agreed to voluntarily withdraw its obesity drug Meridia (sibutramine) from the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in